Wyeth stock down after several setbacks

Wyeth shares are reeling on the news that bifeprunox won't be approved. The stock is down about 7.5 percent since the FDA's "not approvable" letter was announced.

Coming on the heels of regulatory rejection of Pristiq, an antidepressant that was being tested for treatment of menopausal symptoms, and almost coincident with the halting of trials on Wyeth's hepatitis C hopeful (under development with ViroPharma), the bifeprunox blow was severe. Does Wyeth have enough new ideas up its pipeline to help pick up the slack? Some analysts think not; they're predicting a decline in sales and profits in 2010 or 2011 as blockbusters Effexor and Protonix come off patent. "The roof is leaking," says one. Unfortunately, fixing these kinds of holes isn't as easy as replacing a few shingles.

- read the article from The Wall Street Journal (sub. req.)
- and here's the report from Forbes

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.